{
    "organizations": [],
    "uuid": "0a235a5f89c22d2fd0ed9bf9754c862afe32e1a8",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-oncology-venture-exercises-option/brief-oncology-venture-exercises-option-to-in-license-dovitinib-a-phase-3-multi-tyrosine-kinase-inhibitor-idUSFWN1RM074",
    "ord_in_thread": 0,
    "title": "BRIEF-Oncology Venture Exercises Option To In License Dovitinib A Phase 3 Multi Tyrosine Kinase Inhibitor",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9 (Reuters) - Oncology Venture Sweden AB:\n* ONCOLOGY VENTURE EXERCISES OPTION TO IN LICENSE DOVITINIB A PHASE 3 MULTI TYROSINE KINASE INHIBITOR\n* ENTERED INTO AN AGREEMENT WITH NOVARTIS FOR EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE DOVITINIB\n* NOVARTIS WILL RECEIVE AN UPFRONT PAYMENT, DEVELOPMENT MILESTONES, AND ROYALTIES ON SALES.\n* NOVARTIS WILL BE ISSUED A CONVERTIBLE DEBT-TO-EQUITY NOTE IN A SPINOUT COMPANY THAT OV HAS CREATED\n* WILL FURTHER REFINE DOVITINIB DRPÂ® BIOMARKER Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-09T17:29:00.000+03:00",
    "crawled": "2018-04-10T12:59:34.018+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "oncology",
        "venture",
        "sweden",
        "ab",
        "oncology",
        "venture",
        "exercise",
        "option",
        "license",
        "dovitinib",
        "phase",
        "multi",
        "tyrosine",
        "kinase",
        "inhibitor",
        "entered",
        "agreement",
        "novartis",
        "exclusive",
        "global",
        "right",
        "develop",
        "commercialize",
        "dovitinib",
        "novartis",
        "receive",
        "upfront",
        "payment",
        "development",
        "milestone",
        "royalty",
        "sale",
        "novartis",
        "issued",
        "convertible",
        "note",
        "spinout",
        "company",
        "ov",
        "created",
        "refine",
        "dovitinib",
        "biomarker",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}